BioPhtha is a company that specializes in the development and commercialization of sustainable and eco-friendly chemical products derived from biomass. Their focus is on creating alternatives to petroleum-based chemicals, contributing to a more sustainable chemical industry.

BioPhtha

World Health Organization evaluates between 200 and 300 million, the number of people who are visually impaired by diseases against which pharmaceutical treatments are however existing. Many of these conditions have in common to cause permanent vision loss if they are not treated consistently.

The lack of adherence to prescription eye drops is the #1 Unmet Medical need in Ophthalmology. Poor treatment Compliance and Adhesion leads to a worse progression of Eye Diseases. BIOPHTA wants to change the lives of patients suffering from chronic eye diseases by creating a best-in-class solution to reduce the burden of treatments.

We develop a new way of treating the eye, with a novel pharmaceutical platform enabling a continuous Drug Delivery.

Our topical Mucoadhesive Ocular Hydrogel Insert releases drugs on the eye for a one-week period, causing higher efficacy & potency for medications. These Ocular Inserts will help patients to improve their adherence to treatment regimens. It also permits a better yield of the drugs by diminishing the frequency and complexity of eye drops application while generating a continuous and controlled sustained release.

BIOPHTA non-invasive topical ocular inserts are aimed at several ophthalmic indications by allowing better long-term control of diseases.

BIOPHTA

🚀 Exciting News! 🚀

BIOPHTA has successfully closed a €6.5 million Seed round to advance our revolutionary technology for treating eye diseases to clinical stage. This significant milestone was made possible with the support of top European VCs – UI Investissement (via the Pertinence Invest 2 Fund, advised by Merieux Equity Partners), Elaia, GO CAPITAL, with participation from one major ophthalmology player, Unither Pharmaceuticals and HTL Biotechnology, the global leader in production and development of pharma grade biopolymers.

Our first program targets Glaucoma (Phase 1 in 2025), addressing a market valued at $8.7 billion, while our second program focuses on Macular Edema (Phase 1 in 2026), a $9.6 billion market. With these programs, BIOPHTA aims to combat the two leading causes of blindness.

Thank you to our investors and partners for believing in our vision. Together, we are on the path to transforming eye disease treatment! 🌟

Special thanks to Alexandre Boulay, Valérie Calenda, Florian Denis, Valentin T. Fleury and Nathalie Masson.

#Biotech #Investment #Innovation #Ophthalmology #EyeHealth #BIOPHTA #VCFunding #Glaucoma #MacularEdema 
Read the full press release: 
https://lnkd.in/eDUdhgDX

📢 BIOPHTA will be attending the 2024 BIO international convention next week (June3-6) 

👉Book a meeting now 📆 with Jean GARREC in San Diego and join us on our mission to fight blindness 👁



#BIOUS #biotech #ophthalmology #glaucoma #biotechnology #retina #glaucoma #drugdelivery

📢 Join our team and take part in BIOPHTA’s cause to fight blindness ! 👁 

👨‍🔬 We are looking for a 𝐧𝐨𝐧-𝐜𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐝𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭 𝐦𝐚𝐧𝐚𝐠𝐞𝐫 to support our development program ⚗ 

For more information, please apply here :
👉 https://lnkd.in/eEuyteGW

📢 Join our team and take part in BIOPHTA’s cause to fight blindness ! 👁

👨‍🔬 We are looking for a 𝐂𝐌𝐂 𝐝𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭 𝐦𝐚𝐧𝐚𝐠𝐞𝐫 to support our development program ⚗

For more information, please apply here :
👉 https://lnkd.in/ejNFjx3S

📢 Join our team and take part in BIOPHTA’s cause to fight blindness ! 👁

👨‍🔬 We are looking for an 𝐚𝐧𝐚𝐥𝐲𝐭𝐢𝐜𝐚𝐥 𝐝𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭 𝐦𝐚𝐧𝐚𝐠𝐞𝐫 to support our development program ⚗

For more information, please apply here :
👉 https://lnkd.in/eTe8c8G8

Metric
Company Name	BioPhtha
Symbol
MSH ID	COM:BIOPHTA
Market	PRIVATE
Sector	Basic Materials & Materials
Industry	Chemical Manufacturing
Country	FR
Stage
Employee Count	4
Website	biophta.com
LinkedIn	biophta
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:BIOPHTA

BioPhtha

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue